Allogene Therapeutics
ALLO
170 hedge funds and large institutions have $301M invested in Allogene Therapeutics in 2025 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 64 increasing their positions, 42 reducing their positions, and 30 closing their positions.
192% more call options, than puts
Call options by funds: $444K | Put options by funds: $152K
52% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 42
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
0.65% more ownership
Funds ownership: 89.98% → 90.63% (+0.65%)
2% less funds holding
Funds holding: 174 → 170 (-4)
10% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 30
25% less capital invested
Capital invested by funds: $402M → $301M (-$100M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$19.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$10.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$9.15M |
| 4 |
Goldman Sachs
New York
|
+$7.06M |
| 5 |
JP Morgan Chase
New York
|
+$2.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$30.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.41M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$3.19M |
| 4 |
Two Sigma Investments
New York
|
-$1.2M |
| 5 |
Nordea Investment Management
Stockholm,
Sweden
|
-$986K |
ALLO Hedge Fund Activity: Q1 2025 in Review
170 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2025, worth a combined $301M — down 25% from $402M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ALLO and 27 opened new positions — a net loss of 3 holders — while 42 trimmed existing stakes and 64 added.
The largest buyer was Darwin Global Management, opening a new position worth an estimated $19.7M. The largest seller was Fidelity Investments, cutting an estimated $30.9M.
- 170 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2025, down from 174 in Q4 2024.
- Funds reported $301M of Allogene Therapeutics stock for Q1 2025, down 25% quarter-over-quarter.
- 27 funds opened new Allogene Therapeutics positions in Q1 2025 and 30 closed out, a net change of -3 holders.
- The largest Allogene Therapeutics buyer in Q1 2025 was Darwin Global Management, an estimated $19.7M added.
- The largest Allogene Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $30.9M sold.
Based on aggregated 13F filings for Q1 2025.